AstraZeneca is to abandon its late-stage diabetes drug Galida after new results raised doubts about its safety.Galida is a PPAR …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

